{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:06:40Z","timestamp":1789596400384,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"DOI":"10.1186\/s13054-024-05152-2","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T12:24:38Z","timestamp":1731327878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Length of hospital and intensive care unit stay in patients with invasive candidiasis and\/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials"],"prefix":"10.1186","volume":"28","author":[{"given":"Patrick M.","family":"Honor\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Fort\u00fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin H.","family":"Kollef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pullman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Bielicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Dickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Manamley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Sandison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"issue":"7","key":"5152_CR1","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/jac\/dkad139","volume":"78","author":"A Soriano","year":"2023","unstructured":"Soriano A, Honore PM, Puerta-Alcalde P, Garcia-Vidal C, Pagotto A, Goncalves-Bradley D. PE V: invasive candidiasis: current clinical challenges and unmet needs in adult populations. J Antimicrob Chemother. 2023;78(7):1569\u201385.","journal-title":"J Antimicrob Chemother"},{"issue":"15","key":"5152_CR2","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMra1315399","volume":"373","author":"BJ Kullberg","year":"2015","unstructured":"Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015;373(15):1445\u201356.","journal-title":"N Engl J Med"},{"issue":"1","key":"5152_CR3","doi-asserted-by":"publisher","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","volume":"4","author":"PG Pappas","year":"2018","unstructured":"Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4(1):18026.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"5152_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","volume":"23","author":"M Bassetti","year":"2019","unstructured":"Bassetti M, Giacobbe DR, Vena A, Trucchi C, Ansaldi F, Antonelli M, Adamkova V, Alicino C, Almyroudi MP, Atchade E, et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit Care. 2019;23(1):219.","journal-title":"Crit Care"},{"issue":"10","key":"5152_CR5","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","volume":"25","author":"P Koehler","year":"2019","unstructured":"Koehler P, Stecher M, Cornely OA, Koehler D, Vehreschild M, Bohlius J, Wisplinghoff H, Vehreschild JJ. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect. 2019;25(10):1200\u201312.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"5152_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jof3040057","volume":"3","author":"F Bongomin","year":"2017","unstructured":"Bongomin F, Gago S, Oladele R, Denning D. Global and multi-national prevalence of fungal diseases\u2014estimate precision. J Fungi. 2017;3(4):57. https:\/\/doi.org\/10.3390\/jof3040057.","journal-title":"J Fungi"},{"key":"5152_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.vhri.2019.07.002","volume":"21","author":"WNA Wan Ismail","year":"2020","unstructured":"Wan Ismail WNA, Jasmi N, Khan TM, Hong YH, Neoh CF. The economic burden of candidemia and invasive candidiasis: a systematic review. Value Health Reg Issues. 2020;21:53\u20138.","journal-title":"Value Health Reg Issues"},{"key":"5152_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab593","author":"E Rayens","year":"2022","unstructured":"Rayens E, Norris KA. Prevalence and healthcare burden of fungal infections in the United States, 2018. Open Forum Infect Dis. 2022. https:\/\/doi.org\/10.1093\/ofid\/ofab593.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"5152_CR9","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1093\/cid\/ciy776","volume":"68","author":"K Benedict","year":"2019","unstructured":"Benedict K, Jackson BR, Chiller T, Beer KD. Estimation of direct healthcare costs of fungal diseases in the United States. Clin Infect Dis. 2019;68(11):1791\u20137.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"5152_CR10","doi-asserted-by":"publisher","first-page":"ofac097","DOI":"10.1093\/ofid\/ofac097","volume":"9","author":"K Benedict","year":"2022","unstructured":"Benedict K, Whitham HK, Jackson BR. Economic burden of fungal diseases in the United States. Open Forum Infect Dis. 2022;9(4):ofac097.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"5152_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10096-013-1944-3","volume":"33","author":"L Drgona","year":"2014","unstructured":"Drgona L, Khachatryan A, Stephens J, Charbonneau C, Kantecki M, Haider S, Barnes R. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species. Eur J Clin Microbiol Infect Dis. 2014;33(1):7\u201321.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"5152_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/14728214.2022.2142207","volume":"27","author":"D De Bels","year":"2022","unstructured":"De Bels D, Maillart E, Van Bambeke F, Redant S, Honor\u00e9 PM. Existing and emerging therapies for the treatment of invasive candidiasis and candidemia. Expert Opin Emerg Drugs. 2022;27(4):405\u201316.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"4","key":"5152_CR13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2015","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2015;62(4):e1\u201350.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 7","key":"5152_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12039","volume":"18","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19\u201337.","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 7","key":"5152_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/1469-0691.12041","volume":"18","author":"AJ Ullmann","year":"2012","unstructured":"Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18(Suppl 7):53\u201367.","journal-title":"Clin Microbiol Infect"},{"issue":"24","key":"5152_CR16","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1056\/NEJMoa066906","volume":"356","author":"AC Reboli","year":"2007","unstructured":"Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356(24):2472\u201382.","journal-title":"N Engl J Med"},{"key":"5152_CR17","doi-asserted-by":"crossref","unstructured":"Hoenigl M, Salmanton-Garc\u00eda J, Egger M, Gangneux J-P, Bicanic T, Arikan-Akdagli S, Alastruey-Izquierdo A, Klimko N, Barac A, \u00d6zenci V et al: Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM <em>Candida<\/em> III multinational European observational cohort study. The Lancet Infectious Diseases 2023.","DOI":"10.1093\/ofid\/ofac492.038"},{"key":"5152_CR18","unstructured":"Rezzayo (rezafungin) [https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rezzayo#overview]"},{"key":"5152_CR19","unstructured":"US FDA: REZZAYO (rezafungin for injection): Prescribing Information. In.; 2023."},{"key":"5152_CR20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01627-16","author":"T Sandison","year":"2017","unstructured":"Sandison T, Ong V, Lee J, Thye D. Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults. Antimicro Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.01627-16.","journal-title":"Antimicro Agents Chemother"},{"key":"5152_CR21","unstructured":"Mundipharma: REZZAYO 200 mg powder for concentrate for solution for infusion: Summary of Product Characteristics (Draft). In.; 2023."},{"issue":"10370","key":"5152_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","volume":"401","author":"GR Thompson 3rd","year":"2023","unstructured":"Thompson GR 3rd, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, Honore PM, Bassetti M, Pullman J, Chayakulkeeree M, et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023;401(10370):49\u201359.","journal-title":"Lancet"},{"issue":"11","key":"5152_CR23","doi-asserted-by":"publisher","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","volume":"73","author":"GR Thompson","year":"2021","unstructured":"Thompson GR, Soriano A, Skoutelis A, Vazquez JA, Honore PM, Horcajada JP, Spapen H, Bassetti M, Ostrosky-Zeichner L, Das AF, et al. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial. Clin Infect Dis. 2021;73(11):e3647\u201355.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"5152_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1473-3099(23)00551-0","volume":"24","author":"GR Thompson","year":"2024","unstructured":"Thompson GR, Soriano A, Honore PM, Bassetti M, Cornely OA, Kollef M, Kullberg BJ, Pullman J, Hites M, Fort\u00fan J, Horcajada JP. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials. Lancet Infect Dis. 2024;24(3):319\u201328.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"5152_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/myc.12874","volume":"62","author":"N Rae","year":"2019","unstructured":"Rae N, Kenny C, Muldoon EG. Can intravenous antifungal therapy be safely used in the outpatient parenteral antimicrobial therapy (OPAT) setting? Mycoses. 2019;62(3):196\u2013203.","journal-title":"Mycoses"},{"key":"5152_CR26","first-page":"77","volume":"138","author":"F Metzmann","year":"2022","unstructured":"Metzmann F, Muenzer C. Advanced delivery device technology to simplify the reconstitution of lyophilised drugs\u201d. ONdrugDelivery. 2022;138:77\u201382.","journal-title":"ONdrugDelivery"},{"key":"5152_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13613-020-00679-3","volume":"10","author":"MLNG Malbrain","year":"2020","unstructured":"Malbrain MLNG, Langer T, Annane D, Gattinoni L, Elbers P, Hahn RG, De Laet I, Minini A, Wong A, Ince C, Muckart D. Intravenous fluid therapy in the perioperative and critical care setting: executive summary of the international fluid academy (IFA). Ann Intensive Care. 2020;10:1\u201364.","journal-title":"Ann Intensive Care"},{"key":"5152_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jcrc.2020.08.003","volume":"60","author":"IT Peres","year":"2020","unstructured":"Peres IT, Hamacher S, Oliveira FLC, Thom\u00e9 AMT, Bozza FA. What factors predict length of stay in the intensive care unit? Systematic review and meta-analysis. J Crit Care. 2020;60:183\u201394.","journal-title":"J Crit Care"},{"key":"5152_CR29","unstructured":"Thompson GR, Vazquez J, Cornely OA, et al.: Impact of the COVID-19 pandemic on ReSTORE: Phase 3 trial of rezafungin and caspofungin to treat invasive candidiasis and candidaemia. In: 11th Trends in Medical Mycology Congress. Athens, Greece; 2023."}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-05152-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-024-05152-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-05152-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T10:40:03Z","timestamp":1751625603000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-024-05152-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5152"],"URL":"https:\/\/doi.org\/10.1186\/s13054-024-05152-2","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"30 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data supporting the findings of this study are available on request from Sara Dickerson, Sara.Dickerson@mundipharma.com.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data and availability of materials"}},{"value":"Both the STRIVE and ReSTORE trials were in conducted in accordance with current country and local regulations, the International Conference on Harmonisation Good Clinical Practice, and the Declaration of Helsinki. Ethics committees or institutional review boards at participating sites approved the protocols and all amendments. All patients, or their legally authorised representative, provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PMH reports grants or contracts from Baxter, Cytosorbents, and Pfizer; consulting fees from Baxter, Cytosorbents, and Pfizer; honoraria from Baxter, and Cytosorbents; and support for attending meetings from Mundipharma, and Pfizer, outside of the submitted work. MB reports honoraria from and membership of data safety monitoring board or advisory board for Angelini, Cidara, Gilead, Menarini, MSD, Pfizer, and Shionogi, outside of the submitted work. OAC reports grants or contracts from Amplyx, Basilea, Bundesministerium f\u00fcr Bildung und Forschung, Cidara, German Center for Infection Research, European Union Directorate-General for Research and Innovation (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, and Scynexis; consulting fees from AbbVie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, Noxxon, Octapharma, Pardes, Pfizer, Pharma Support America, Scynexis, and Seres; honoraria from Abbott, AbbVie, Al-Jazeera Pharmaceuticals, Astellas, Gilead, Grupo Biotoscana\/United Medical\/Knight, Hikma, MedScape, MedUpdate, Merck\/MSD, Mylan, Noscendo, Pfizer, and Shionogi; payment for expert testimony from Cidara; data safety monitoring board or advisory board membership for Actelion, Allecra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, Pharma Support America, Pulmocide, Shionogi, and The Prime Meridian Group; a patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); stocks from CoRe Consulting; outside of the submitted work. HD reports consulting fees from Pfizer, Gilead, MSD, Mundipharma, Shionogi, Viatris, outside of the submitted work. JF was an advisor\/consultant and received grant support and honoraria for talks on behalf of Astellas Pharma, Gilead Sciences, Merck Sharp & Dohme and Pfizer, outside of the submitted work. MK reports grants from Barnes-Jewish Hospital Foundation and consulting fees from Merck, Pfizer, and Shionogi, outside of the submitted work. PP reports grants from Astellas, Gilead, Scynexis, and Cidara; fees for scientific advisory board from F2G, Matinas, TFF, Basilea outside of the submitted work. JP Reports no conflict of interest. JV reports consulting fees from and membership of data safety monitoring board or advisory board for F2G and consulting fees from Cidara and Scynexis, outside of the submitted work. IB and NM report being employees of Mundipharma. TS reports being an employee of and holding stocks in Cidara Therapeutics. GRT reports grants and consulting fees from Amplyx, Astellas, Cidara, F2G, and Manye; grants from Merck; and data safety monitoring board membership for Pfizer, outside of the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"361"}}